[
  {
    "ts": null,
    "headline": "How Investors May Respond To Eli Lilly (LLY) AI Drug Platform Launch and Oncology Breakthroughs",
    "summary": "In early September 2025, Eli Lilly launched Lilly TuneLab, an advanced AI/ML drug discovery platform, and reported positive Phase 3 results for Jaypirca in CLL/SLL, as well as receiving FDA Breakthrough Therapy designation for olomorasib in advanced NSCLC. The combination of Lilly’s AI platform roll-out and significant oncology pipeline progress signals a shift towards accelerated innovation and collaborative drug development in the pharmaceutical industry. We'll explore how the debut of...",
    "url": "https://finnhub.io/api/news?id=b886fda1d0a0fc4c9709d8976776cadee3ce251894c53ce240d2cf7272404f19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757772212,
      "headline": "How Investors May Respond To Eli Lilly (LLY) AI Drug Platform Launch and Oncology Breakthroughs",
      "id": 136735905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In early September 2025, Eli Lilly launched Lilly TuneLab, an advanced AI/ML drug discovery platform, and reported positive Phase 3 results for Jaypirca in CLL/SLL, as well as receiving FDA Breakthrough Therapy designation for olomorasib in advanced NSCLC. The combination of Lilly’s AI platform roll-out and significant oncology pipeline progress signals a shift towards accelerated innovation and collaborative drug development in the pharmaceutical industry. We'll explore how the debut of...",
      "url": "https://finnhub.io/api/news?id=b886fda1d0a0fc4c9709d8976776cadee3ce251894c53ce240d2cf7272404f19"
    }
  },
  {
    "ts": null,
    "headline": "2 Beaten-Down Stocks to Buy and Hold Forever",
    "summary": "Their prospects look intact despite some recent roadblocks.",
    "url": "https://finnhub.io/api/news?id=513d83fd4adc3c4e996341de8a84ae26920a92cac6e84962f60d79c15775061e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757767500,
      "headline": "2 Beaten-Down Stocks to Buy and Hold Forever",
      "id": 136735797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Their prospects look intact despite some recent roadblocks.",
      "url": "https://finnhub.io/api/news?id=513d83fd4adc3c4e996341de8a84ae26920a92cac6e84962f60d79c15775061e"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Dividend Stocks to Buy in September",
    "summary": "The attraction of these dividend stocks isn't limited to their dividends.",
    "url": "https://finnhub.io/api/news?id=f0a2aa01059a8fa8b98ae1bd8addb0860f3528b0878a0acf910bbc784a82e60d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757763720,
      "headline": "3 No-Brainer Dividend Stocks to Buy in September",
      "id": 136735908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The attraction of these dividend stocks isn't limited to their dividends.",
      "url": "https://finnhub.io/api/news?id=f0a2aa01059a8fa8b98ae1bd8addb0860f3528b0878a0acf910bbc784a82e60d"
    }
  },
  {
    "ts": null,
    "headline": "The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter",
    "summary": "Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.",
    "url": "https://finnhub.io/api/news?id=3523e47bdfa2d6d55df6af8c745a7269fd0047475305b58f18e171b855eabe97",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757745000,
      "headline": "The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter",
      "id": 136733182,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1388387575/image_1388387575.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.",
      "url": "https://finnhub.io/api/news?id=3523e47bdfa2d6d55df6af8c745a7269fd0047475305b58f18e171b855eabe97"
    }
  },
  {
    "ts": null,
    "headline": "BDC Weekly Review: BDCs Busy Bringing Bonds To Market",
    "summary": "BDCs dipped slightly as bond issuance rises and leverage builds to support income amid rate shifts. Read why these trends matter for the sector outlook.",
    "url": "https://finnhub.io/api/news?id=65805de9d470d92db4ef72310fbda5549dad670c295beb5bbfcd5d14b17e0136",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757743165,
      "headline": "BDC Weekly Review: BDCs Busy Bringing Bonds To Market",
      "id": 136733121,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163573192/image_2163573192.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BDCs dipped slightly as bond issuance rises and leverage builds to support income amid rate shifts. Read why these trends matter for the sector outlook.",
      "url": "https://finnhub.io/api/news?id=65805de9d470d92db4ef72310fbda5549dad670c295beb5bbfcd5d14b17e0136"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: GLP-1's Concerns Are Overblown",
    "summary": "Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation. Find out why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=b7791f55da1a29b7c302e06ca07e2489cdec8513804a23bfe0935a7773b5f5c1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757738467,
      "headline": "Novo Nordisk: GLP-1's Concerns Are Overblown",
      "id": 136732753,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154031430/image_2154031430.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation. Find out why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=b7791f55da1a29b7c302e06ca07e2489cdec8513804a23bfe0935a7773b5f5c1"
    }
  }
]